Publications by authors named "Ya-qin Qin"
Article Synopsis
- SARS-CoV-2 variants pose a serious health threat, leading to high rates of illness and death, prompting the need for genomic analysis.
- Next-generation sequencing and phylogenetic analysis were used to study 80 SARS-CoV-2 genomes from COVID-19 patients, revealing a novel variant with specific mutations in the spike glycoprotein.
- These mutations (H625R and S50L) could enhance the spike protein's flexibility and potentially alter its interaction with the ACE2 receptor, indicating ongoing evolution of the virus.
Article Synopsis
- CD8+ T cells play a crucial role in controlling HIV-1, and understanding their metabolism is important for developing therapies for those living with HIV-1.
- High plasma glutamate levels are found in people living with HIV-1, correlating with larger HIV-1 reservoirs and decreased CD8+ T cell function.
- The study indicates that targeting glutamate metabolism, particularly its effects on CD8+ T cell activity via the mTORC1 pathway, could offer new therapeutic strategies to enhance anti-HIV responses.
Article Synopsis
- * A study analyzed 118 patients with confirmed SARS-CoV-2 infections to assess various clinical indicators during their hospital stay.
- * Findings revealed that specific blood markers (high ALT, AST, low CD4+, CD8+) correlated with a longer duration of detectable viral RNA, suggesting these indicators may help predict how long a patient will carry the virus.
Article Synopsis
- Recent research indicates that CD8+ T cells are crucial in controlling HIV-1 reservoirs in individuals on antiretroviral therapy, although their exact mechanisms are still unclear.
- In a study of 60 virologically suppressed HIV-1 patients, certain CD8+ T cell subsets were found to correlate with levels of HIV-1 DNA and RNA, revealing that specific central and terminally differentiated memory cells behaved differently in their responses.
- The findings suggest that CCL5-secreting CD8+ T cells may play a key role in limiting HIV-1 reservoirs, paving the way for new CD8+ T cell-based treatments aimed at curing HIV-1 infection.
Sorafenib has long been the only approved systemic therapy for advanced hepatocellular carcinoma (HCC), but most patients show primary or acquired drug resistance. In the present study, RNA was extracted from sorafenib-resistant and -sensitive clones of the HCC cell lines HepG2 and Huh7. Protein-protein interaction networks of the up- and down-regulated genes common to the two sorafenib-resistant cell lines were extracted and subjected to modular analysis in order to identify functional modules.
View Article and Find Full Text PDFItch is a common symptom in patients with skin and systemic diseases, but the effective treatment is limited. Here, we evaluated the anti-itch effects of the botulinum toxin type A (BoNT/A) using acute and chronic dry skin itch mouse models, which were induced by compound 48/80, chloroquine, and a mixture of acetone-diethylether-water treatment, respectively. Pretreatment of intradermal BoNT/A exerted long-term inhibitory effects on compound 48/80-induced and chloroquine-induced acute itch on days 1, 3, 7, and 14, but not on day 21, in mice.
View Article and Find Full Text PDF[The efficacy of imatinib mesylate for 124 patients with chronic myeloid leukemia in accelerated and blastic phase].
Zhonghua Xue Ye Xue Za Zhi
November 2007
Objectives: To evaluate the efficacy and safety of imatinib mesylate (imatinib) for patients with Philadelphia chromosome-positive (Ph+ ) chronic myeloid leukemia (CML) in accelerated and blastic phase.
Methods: Seventy-five Ph+ CML patients in accelerated phase and 49 in blastic phase were treated with 400 mg or 600 mg of imatinib once daily.
Results: For patients in accelerated phase, the cumulative hematological response (HR) rate was 93.
[Relationship among pathological changes in Liver tissues and level of serum HBV DNA, HBeAg and ALT of 194 patients with chronic hepatitis B].
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
March 2007
Objective: To study the relationships among pathological and immunohistochemical changes in liver tissues, and the HBeAg, HBV DNA, ALT level in the patients with chronic hepatitis B.
Methods: Pathological and immunohistochemical examinations of liver tissue liver function tests, serum HBV and HBV DNA detection were performed in 194 patients with chronic hepatitis B.
Results: There was significant difference between the serum HBeAg positive group and the negative group in G2, G3-4 S2, S3-4 in liver tissues; The serum HBV DNA level of the groups S0 and S1-4, and the hepatic activity index between the groups G0-1 and G2-4 were significantly different.
Aim: To investigate the distribution of HBV genotypes and their YMDD mutations in Guangxi Zhuang population, China, and to study the relationship between HBV genotypes and clinical types of HB, ALT, HBV DNA, HBe system as well as the curative effect of Lamivudine (LAM) on hepatitis B.
Methods: A total of 156 cases were randomly chosen as study subjects from 317 patients with chronic hepatitis B (CHB). HBV genotypes were determined by PCR-microcosmic nucleic acid cross-ELISA.
YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines.
World J Gastroenterol
February 2005
Aim: To polymerase P region (YMDD) mutations of hepatitis B virus gene (HBV DNA) in patients with chronic hepatitis B (CHB) untreated with antiviral medicines and to explore its correlation with pre-c-zone mutations, HBV genotypes and HBV DNA level, and to observe its curative effect.
Methods: A total of 104 cases (38 cases in group of familial aggregation and 66 cases in group of non-familial aggregation) were randomly chosen from 226 patients with CHB who did not receive the treatment of lamivudine (LAM) and any other antivirus drugs within the last one year. Their serum YMDD mutations were detected by microcosmic nucleic acid and cross-nucleic acid quantitative determination, HBV genotypes by PCR-microcosmic nucleic acid cross-ELISA, HBV DNA quantitative determination and fluorescence ration PCR analysis, hepatitis B virus markers (HBVM) by ELISA.